Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Renal Biomarkers Market – Insights
A biomarker can be defined as a biological characteristic of an organism that is measured as an indicator of normal biological process. Renal biomarkers are an important tool in diagnosis of various kidney diseases and detection of acute and chronic kidney injuries. An ideal renal biomarker must be able to detect kidney disorders at the initial stage.
The global renal biomarkers market is estimated to account for US$ 1,094.5 Mn in terms of value in 2019 and is expected to reach US$ 1,894.2 Mn by the end of 2027.
Global Renal Biomarkers Market: Drivers
Increasing prevalence of chronic kidney diseases is expected to propel growth of the global renal biomarkers market over the forecast period. For instance, according to European Renal Association – European Dialysis and Transplant Association’s data in 2018, over 850 million people worldwide have some form of kidney disease.
Moreover, increasing rate of progression of chronic kidney disease in children is also expected to aid in growth of the market. For instance, according to the study, ‘Risk Factors and Rate of Progression of CKD in Children’, published in June 2019 in Kidney International Reports, 38% children experienced progression of chronic kidney disease within 2 years of follow-up.
North America region held dominant position in the global renal biomarkers market in 2018, accounting for 32.5% share in terms of value, followed by Europe.
Global Renal Biomarkers Market: Restraints
Low sensitivity and specificity of biomarkers is expected to hinder growth of the global renal biomarkers market. For instance, some renal biomarkers such as L-18 are more specific although are not very sensitive, while other biomarkers such as osteopontin are highly sensitive though they are not specific.
Moreover, use of unreliable, imperfect gold standards is also expected to limit growth of the market. Serum creatinine, although having low sensitivity and specificity, is used as gold standard. Serum creatinine does not distinguish whether the reason for rise in levels is due to renal injury or other non-renal causes such as hemodynamic (obstructive uropathy) mediated changes. Moreover, serum creatinine is also not effective in renal recovery and injury.
Global Renal Biomarkers Market: Opportunities
Players in the market may focus on collaborating with academia in order to identify new biomarkers that will facilitate drug development.
Moreover, R&D in renal biomarkers is also expected to aid in growth of the market. For instance, in February 2020, researchers from NLC India Limited, National Institute of Mental Health and Neurosciences, and Madras Diabetes Research Foundation (MDRF), Chennai, India reported identifying urine based biomarker, Micro albuminuria, for early prediction of diabetic kidney failure.
Functional biomarkers segment in the global renal biomarkers market was valued at US$ 543.6 Mn in 2018 and is expected to reach US$ 1,057.3 Mn by 2027 at a CAGR of 7.6% during the forecast period.
Market Trends/Key Takeaways
Players in the market are focused on developing feline renal biomarkers. For instance, in February 2020, Antech Diagnostics, a part of Mars Petcare, launched Antech SDMA (symmetric dimethylarginine), a feline renal biomarker for early diagnosis, staging and monitoring of chronic kidney disease.
Major players in the market are also focused on conducting studies for R&D of renal biomarkers. For instance, in December 2019, SphingoTec GmbH reported the publication of novel study results of its proprietary kidney function biomarker penKid in BMC Emergency Medicine.
Global Renal Biomarkers Market: Competitive Landscape
Major players operating in the global renal biomarkers market include, Beckman Coulter, Inc., (Danaher Corporation), Thermo Fisher Scientific Inc., Abbott Laboratories, BIOPORTO A/S, Astute Medical, Inc., Randox Laboratories Ltd., and SphingoTec GmbH.
Global Renal Biomarkers Market: Key Developments
Major players in the market are focused on launching new products to expand their product portfolio. For instance, in January 2020, SphingoTec GmbH launched IB10 sphingotest penKid, a CE-IVD-marked point-of-care test for Proenkephalin, a renal biomarker.
Players in the market are also focused on approval and launch of new biomarkers to expand their product portfolio. For instance, in November 2019, BioPorto A/S announced to supplement its pediatric 510(k) application to the U.S. FDA with additional data for regulatory clearance of The NGAL Test (a biomarker test) for pediatric risk assessment of acute kidney injury.